Your browser doesn't support javascript.
loading
Results of a Phase 1/2 Study in Metastatic Renal Cell Carcinoma Patients Treated with a Patient-specific Adjuvant Multi-peptide Vaccine after Resection of Metastases.
Rausch, Steffen; Gouttefangeas, Cécile; Hennenlotter, Jörg; Laske, Karoline; Walter, Kerstin; Feyerabend, Susan; Chandran, Premachandran Anoop; Kruck, Stephan; Singh-Jasuja, Harpreet; Frick, Annemarie; Kröger, Nils; Stevanovic, Stefan; Stenzl, Arnulf; Rammensee, Hans-Georg; Bedke, Jens.
Afiliação
  • Rausch S; Department of Urology, Eberhard Karls University, Tübingen, Germany.
  • Gouttefangeas C; Department of Immunology, Eberhard Karls University, Tübingen, Germany; German Cancer Consortium (DKTK), Partnerstandort Tübingen, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hennenlotter J; Department of Urology, Eberhard Karls University, Tübingen, Germany; German Cancer Consortium (DKTK), Partnerstandort Tübingen, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Laske K; Department of Immunology, Eberhard Karls University, Tübingen, Germany.
  • Walter K; Department of Urology, Eberhard Karls University, Tübingen, Germany.
  • Feyerabend S; Department of Urology, Eberhard Karls University, Tübingen, Germany.
  • Chandran PA; Department of Immunology, Eberhard Karls University, Tübingen, Germany.
  • Kruck S; Department of Urology, Eberhard Karls University, Tübingen, Germany.
  • Singh-Jasuja H; Department of Immunology, Eberhard Karls University, Tübingen, Germany.
  • Frick A; Department of Immunology, Eberhard Karls University, Tübingen, Germany.
  • Kröger N; Department of Urology, University of Greifswald, Greifswald, Germany.
  • Stevanovic S; Department of Immunology, Eberhard Karls University, Tübingen, Germany; German Cancer Consortium (DKTK), Partnerstandort Tübingen, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Stenzl A; Department of Urology, Eberhard Karls University, Tübingen, Germany; German Cancer Consortium (DKTK), Partnerstandort Tübingen, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Rammensee HG; Department of Immunology, Eberhard Karls University, Tübingen, Germany; German Cancer Consortium (DKTK), Partnerstandort Tübingen, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Bedke J; Department of Urology, Eberhard Karls University, Tübingen, Germany; German Cancer Consortium (DKTK), Partnerstandort Tübingen, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: jens.bedke@med.uni-tuebingen.de.
Eur Urol Focus ; 5(4): 604-607, 2019 07.
Article em En | MEDLINE | ID: mdl-28988765
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Adjuvantes Imunológicos / Vacinas Anticâncer / Neoplasias Renais Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Adjuvantes Imunológicos / Vacinas Anticâncer / Neoplasias Renais Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article